← All reportsView on Symbol
ANIP

ANIP

Medium conviction

ANI Pharmaceuticals, Inc.

Healthcare · NASDAQ

$1.8B mkt cap

Brief updated Today

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also man

Decifer Research·Data summary

ANIP is a medium-conviction name in healthcare_biotech_devices

ANIP sits at the intersection of key themes currently active in the market. The scoring engine rates it medium based on how well the active market forces line up with its business, plus available fundamental data. Financial metrics and analyst consensus provide additional context.

Why now

The market forces active right now are aligned with the company's core business exposure. The timing reflects the intersection of theme strength and available catalyst data.

Key risks

Data availability limits full scoring across all dimensions. Market forces can reverse rapidly; theme exposure does not guarantee the price follows. Fundamental valuation data may not reflect the most recent quarterly results.

What to watch

Monitor conviction score changes, especially the macro and analyst dimensions. Earnings guidance updates and analyst consensus shifts are the primary near-term catalysts.

39Medium conviction Conviction
macro
5/25
analyst
18/38
momentum
8/20
forward catalyst
0/15
valuation
18/23
highs
-5/12
news catalyst
3/12
options flow
0/12
peer network
0/8
counter thesis
0/3
Key financials
Revenue growth (YoY)2046.0%
Gross margin6594.0%
Operating margin1338.0%
Net margin971.0%
P/E ratio18.5x
Return on equity1732.0%
FCF yield890.0%
Debt / equity0.6x
EV / sales2.0x
Valuation
Analyst consensusBUY
DCF fair value$1013
Next EPS estimate$2.51
Theme exposure
Healthcare, Biotech & DevicesDirect

ANI Pharmaceuticals, Inc. operates in drug manufacturers - specialty & generic. That places it inside the Healthcare, Biotech & Devices story.

Macro context

Trump Criticized Biden for Draining America’s Oil Reserves. They’re Now at a 43-Year Low Amidst a Middle East War.

US Strategic Petroleum Reserve levels have fallen to a 43-year low, reducing the government's capacity to buffer oil price shocks at a time of active Middle East conflict. This structural vulnerability in US energy policy raises concerns about energy security and the ability to respond to supply disruptions.

6d ago

Trump Criticized Biden for Draining America’s Oil Reserves. They’re Now at a 43-Year Low Amidst a Middle East War.

US Strategic Petroleum Reserve levels have fallen to a 43-year low amid an active Middle East conflict, reducing America's buffer capacity against oil supply disruptions. This constrains the US government's ability to intervene in energy markets during a period of elevated geopolitical risk.

6d ago

U.S. Central Command Posts On X "At 5:45 p.m. ET today, Islamic Revolutionary Guard Corps forces launched multiple ballistic missiles from Iran in an attempted surprise attack on U.S. forces based in the Middle East. All Iranian missiles were successfully intercepted. U.S. forces remain vigilant and at a high state of readiness."

Iranian IRGC forces launched a ballistic missile attack on U.S. military positions in the Middle East, which was fully intercepted according to U.S. Central Command. This represents a direct state-on-state military strike against U.S. forces, dramatically escalating regional tensions and raising the risk of broader conflict.

6d ago

Equities Lower Intraday Ahead of Fed Decision, Major Tech Earnings

The equities market is experiencing intraday losses ahead of the highly anticipated Federal Reserve decision, which could significantly impact market direction and investor sentiment. The decision, coupled with major tech earnings reports, is poised to influence the overall economic outlook.

5d ago

Analyst intelligence
7 Buy3 Hold0 Sell
Earnings intelligence

Earnings surprises

+60.2%

2026-05

+17.1%

2026-02

+17.2%

2025-11

+30.4%

2025-08

+24.1%

2025-05

Generated Mon, 03 Aug 2026 17:59:24 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.